Price Chart

Profile

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products.  In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
URL N/A
Investor Relations URL https://www.citiusonc.com/overview/default.aspx
HQ State/Province New York
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Aug. 09, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products.  In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
URL N/A
Investor Relations URL https://www.citiusonc.com/overview/default.aspx
HQ State/Province New York
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Aug. 09, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A